Insights
Insights From Our Experts
Articles
From Trust to Treatment: How Culture Shapes Patient Decisions in APAC
In the diverse and dynamic Asia-Pacific (APAC) region, healthcare behaviors are shaped by more than just economics or access—they are deeply influenced by cultural values. Yet many commercial, market access, and medical affairs teams within pharmaceutical…
Most Favored Nation Pricing | Insights and Implications for Manufacturers
The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers. Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing…
From Science to Value: Strategic Asset Valuation for Biotech Licensing and Fundraising
Early-stage biotech companies face a critical challenge: transforming promising science into compelling commercial value. Investors and partners fund future potential, not mechanisms—especially when data is limited and market entry is years away. This white paper, authored…
Harnessing the Digital Voice: High-Impact Social Listening for Pharma in the Diverse APAC Landscape
Healthcare engagement in the Asia-Pacific (APAC) region is increasingly shifting from traditional settings to digital platforms, patient forums, and social media feeds. Despite APAC accounting for over half of global social media users, its pharmaceutical sector…
Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025
Mike Ryan, General Manager, Europe, at EVERSANA, connected in a conversation with PharmaShots before Reuters Pharma 2025 in Barcelona, which ran 9-11 April 2025. Mike’s discussion focused on the history of EVERSANA and how the company…
CASE STUDY: Transforming Clinical Trials with EVERSANA
Modernizing Clinical Trials to Accelerate Access Clinical trials are essential for bringing life-changing therapies to market, yet traditional models often present significant barriers for both participants and trial sites. A leading pharmaceutical manufacturer partnered with EVERSANA…
Generic Substitution in Southeast Asia and Emerging Markets: Key Insights for Strategic Decision-Making
Are you curious about the evolving landscape of generic substitution in Southeast Asia and other emerging markets? Our latest white paper, Generic Substitution in Southeast Asia and Emerging Markets: Key Insights for Strategic Decision-Making, delves into the…
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have…
Maximizing Sales with AI: A Strategic Roadmap for Success
Artificial intelligence (AI) is transforming the sales landscape, offering innovative ways to boost efficiency, enhance decision-making and drive revenue growth. With AI adoption in sales ranking among the top three functions across industries, organizations must leverage…
Rare Disease Care in India: A Path to Positive Impact
India’s rare disease market is on the rise, expected to grow from $2.74 billion to $6.6 billion by 2030. However, challenges such as delayed diagnoses, limited treatment accessibility and underutilized government funds continue to impact patient…